DOCSLIB.ORG

PASS Information

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
PASS Information PASS Information Title Aclidinium Bromide Post-Authorisation Safety Study to Evaluate the Risk of Cardiovascular Endpoints: Common Study Protocol Protocol version Version 4.0 (20 March 2019) identifier Date of last version 17 February 2017, version 3.0 of protocol (version 2.2, 02 June 2015; version 2.1, 29 July 2014; version 2.0, 14 April 2014; version 1.1, 19 April 2013) EU PAS register ENCEPP/SDPP/6559; 23 May 2014 number Active substance Aclidinium bromide (ATC code: R03BB05) Aclidinium bromide/formoterol fumarate dihydrate (ATC code: R03AL05) Medicinal product Eklira® Genuair®/Bretaris® Genuair® Duaklir® Genuair®/Brimica® Genuair® Product reference Eklira® Genuair®: H0002211 Bretaris® Genuair®: H0002706 Duaklir® Genuair®: H0003745 Brimica® Genuair®: H0003969 Procedure number Eklira® Genuair®: EMEA/H/C/002211 Bretaris® Genuair®: EMEA/H/C/002706 Duaklir® Genuair®: EMEA/H/C/003745 Brimica® Genuair®: EMEA/H/C/003969 Marketing AstraZeneca AB authorisation holder(s) Joint PASS No Research question The overall objective of this post-authorisation safety study (PASS) is and objectives to evaluate the potential cardiovascular safety concerns and all-cause mortality described in the risk management plan for aclidinium bromide, through sequential, cohort substudies for each endpoint of interest. Specific objectives are as follows: . To compare the risk of congestive heart failure (CHF); acute myocardial infarction (AMI), including community coronary heart disease (CHD) death; stroke; and all-cause mortality in patients with chronic obstructive pulmonary disease (COPD) initiating treatment with aclidinium bromide (monotherapy; concomitant with formoterol not in fixed-dose combination; and fixed-dose combination with formoterol, when available) and other inhaled COPD medications with the risk in patients with COPD initiating treatment with long- acting beta-agonists (LABAs). To compare the risk of congestive heart failure, acute myocardial infarction, stroke, and all-cause mortality in patients with COPD initiating treatment with aclidinium bromide (monotherapy; concomitant with formoterol not in fixed-dose combination; and fixed-dose combination with formoterol, when available) with the CONFIDENTIAL 1 of 82 risk in patients with COPD initiating other inhaled treatments for COPD. To evaluate the effect of duration of each of the study medications on the risk of each individual endpoint. When the fixed-dose combination of aclidinium/formoterol becomes available, new users will be included in the cohort for evaluation. A new additional endpoint of cardiac arrhythmias is planned to be evaluated for this cohort. Country(-ies) of United Kingdom; other country(ies) to be determined study Author Cristina Rebordosa, MD, PhD Cristina Varas-Lorenzo, MD, PhD RTI Health Solutions Av. Diagonal 605, 9-1 08028 Barcelona, Spain Telephone: +34.93.362 2807 Fax: +34.93.760.8507 E-mail: [email protected] Marketing Authorisation Holder(s) Marketing AstraZeneca AB authorisation SE-151 85 Södertälje holder(s) Sweden MAH contact person Magnus Ysander AstraZeneca EU QPPVEU AstraZeneca AB SE-151 85 Södertälje Sweden The protocol Aclidinium Bromide Post-Authorisation Safety Study to Evaluate the Risk of Cardiovascular Endpoints: Common Study Protocol, Version 2.1, was approved as part of the granted marketing authorisation of fixed-dose combination Duaklir Genuair as a new medicinal product for human use by the European Medicines Agency in November 2014. Version 2.2 clarified AstraZeneca as the new MAH. Version 3.0 reflected updates of project milestones. The current amendment, Version 4.0, updates project milestones and sampling strategy. CONFIDENTIAL 2 of 82 Approval Page-RTI Health Solutions Project Title: Acl idinium Bromide Post-Authorisation Safety Study to Evaluate the Risk of Cardiovascular Endpoints, Common Study Protocol, Version 4.0 Protocol ID Number: D6560R00004 (formerly M/34273/44) Authors Cristina Rebordosa, MD, PhD; Cristina Varas-Lorenzo, MD, PhD; Jordi Castellsague, MD, MPH; Susana Perez-Gutthann, MD, PhD (RTI Health Solutions) Version Date: ~o March 2019 The following people have reviewed the protocol and give their approval: - C ) h 1\-fl..cb-f- Z& I 'J Cristina Rebordosa, MD, PhD Date Director, Epidemiology 25 'HAl2C\-l 2.0\9 Susana Perez-Gutthann MD, PhD Date Vice-President, Global Head Epidemiology CONFIDENTIAL 1 of R? Aclidinium Bromide Post-Authorisation Safety Study to Evaluate the Risk of Cardiovascular Endpoints: Common Study Protocol, Version 4.0, 20 March 2019 1 Table of Contents 1 Table of Contents....................................................................................... 5 List of Tables..................................................................................................... 6 List of Figures ................................................................................................... 6 2 List of Abbreviations.................................................................................. 7 3 Responsible Parties ................................................................................... 9 4 Abstract..................................................................................................... 9 5 Amendments and Updates ....................................................................... 14 6 Milestones and Timeline .......................................................................... 17 7 Rationale and Background....................................................................... 19 8 Research Question and Objectives........................................................... 21 9 Research Methods ................................................................................... 21 9.1 Study Design ...................................................................................... 22 9.1.1 Definition of New Users.......................................................... 24 9.1.2 Choice of Comparator Drugs................................................... 25 9.1.3 Definition of Index Prescription ............................................... 26 9.2 Setting............................................................................................... 27 9.2.1 Study Cohort ........................................................................ 27 9.2.2 Health Care Databases........................................................... 30 9.3 Variables............................................................................................ 31 9.3.1 Study Endpoints.................................................................... 31 9.3.2 Exposure Assessment ............................................................ 36 9.3.3 Risk Factors and Confounding ................................................. 37 9.4 Data Sources...................................................................................... 40 9.5 Study Size.......................................................................................... 40 9.6 Data Collection and Management .......................................................... 45 9.7 Data Analysis...................................................................................... 45 9.7.1 Cohort Description................................................................. 45 9.7.2 Cohort Analysis..................................................................... 45 9.7.3 Subgroup Analyses................................................................ 49 9.7.4 Effect of Duration .................................................................. 49 9.7.5 Errors, Inconsistent Values, and Missing Data ........................... 50 9.8 Quality Control.................................................................................... 50 9.9 Limitations of the Research Methods...................................................... 50 9.10 Other Aspects..................................................................................... 52 10 Protection of Human Subjects and Other Good Research Practice ........... 52 10.1 Informed Consent ............................................................................... 52 10.2 Participant Confidentiality..................................................................... 53 10.3 Compensation..................................................................................... 53 11 Management and Reporting of Adverse Events/Adverse Reactions ......... 53 12 Plans for Disseminating and Communicating Study Results..................... 53 13 References............................................................................................... 54 CONFIDENTIAL 5 of 82 Aclidinium Bromide Post-Authorisation Safety Study to Evaluate the Risk of Cardiovascular Endpoints: Common Study Protocol, Version 4.0, 20 March 2019 Annex 1. List of Stand-Alone Documents......................................................... 60 Annex 2. ENCePP Checklist for Study Protocols............................................... 61 Annex 3. Codes for Medications and Diagnoses............................................... 69 Annex 4. Proposed European Databases ......................................................... 74 Annex 5. Potential Confounding and Risk Factors ........................................... 77 List of Tables Table 1. First-Choice Medications in the Initial Management of COPD According to European Clinical Guidelines ...............................................................26 Table 2. Diagnosis Codes to Identify Patients With COPD ....................................28 Table 3. Exclusion
Load more

Recommended publications
  • Spirometry Protocol and Software Training Handout
    SPIROMETRY PROTOCOL AND SOFTWARE TRAINING HANDOUT Spirometry Protocol Key Points in Performing Spirometry ▪ Always demonstrate the maneuver ▪ Prompt the participant to BLAST out the air ▪ Continue by having the participant PUSH out the air ▪ Continue until the balloon bursts or at least six seconds Getting ready to do Spirometry Subjects will be instructed to not use any bronchodilator medicines for at least 4 hours prior to the appointment (in the case of salmeterol [Serevent] or Fomoterol (foradil)or Tritoprium (Spiriva) avoid for 12 hours prior to the test). Bronchodilator medicines include: Short acting bronchodilators Albuterol (ventolin, proventil, airet, volmax tablet) Levalbuterol (xopenex) Metaproterenol (alupent) Pirbuterol (maxair) Terbutaline (brethaire, brethine, bricanyl) Isoetharine (bronkosol) Ipratropium (atrovent) Ipratropium and albuterol combination (Combivent) Isoproteranol (isuprel) Primatine 1 CHW Educational Protocols – Spirometry Protocol and Software Training Handout Bitolterol (tornalate) Long acting bronchodilator Salmeterol (serevent) Fomoterol (foradil) Tritoprium (Spiriva) Bronchodilators should be avoided because they can affect the spirometry results. If the patient is having symptoms from asthma and needs to use the medicine, ask that the medicine be used 4 hours before the visit, so that the next dose is due during the visit. Patients can then do the spirometry and then the patient can take the medicine after the test is completed. When scheduling the follow-up spirometry visit, if at all possible, try to make the visit at the same time as the initial baseline visit. 1. Preparing the Computer 1. Check to see if the time and date on the lower right hand corner is current. If the date and time is NOT, the spirometer will NOT sync with the computer or the Easy One software.
    [Show full text]
  • 18 December 2020 – to Date)
    (18 December 2020 – to date) MEDICINES AND RELATED SUBSTANCES ACT 101 OF 1965 (Gazette No. 1171, Notice No. 1002 dated 7 July 1965. Commencement date: 1 April 1966 [Proc. No. 94, Gazette No. 1413] SCHEDULES Government Notice 935 in Government Gazette 31387 dated 5 September 2008. Commencement date: 5 September 2008. As amended by: Government Notice R1230 in Government Gazette 32838 dated 31 December 2009. Commencement date: 31 December 2009. Government Notice R227 in Government Gazette 35149 dated 15 March 2012. Commencement date: 15 March 2012. Government Notice R674 in Government Gazette 36827 dated 13 September 2013. Commencement date: 13 September 2013. Government Notice R690 in Government Gazette 36850 dated 20 September 2013. Commencement date: 20 September 2013. Government Notice R104 in Government Gazette 37318 dated 11 February 2014. Commencement date: 11 February 2014. Government Notice R352 in Government Gazette 37622 dated 8 May 2014. Commencement date: 8 May 2014. Government Notice R234 in Government Gazette 38586 dated 20 March 2015. Commencement date: 20 March 2015. Government Notice 254 in Government Gazette 39815 dated 15 March 2016. Commencement date: 15 March 2016. Government Notice 620 in Government Gazette 40041 dated 3 June 2016. Commencement date: 3 June 2016. Prepared by: Page 2 of 199 Government Notice 748 in Government Gazette 41009 dated 28 July 2017. Commencement date: 28 July 2017. Government Notice 1261 in Government Gazette 41256 dated 17 November 2017. Commencement date: 17 November 2017. Government Notice R1098 in Government Gazette 41971 dated 12 October 2018. Commencement date: 12 October 2018. Government Notice R1262 in Government Gazette 42052 dated 23 November 2018.
    [Show full text]
  • Validation of New Analytical Methodology for Determining Fenoterolhydrobromide by HPLC: Application in Pharmaceutical Products
    Artigo Original/Original Article Validation of new analytical methodology for determining fenoterolhydrobromide by HPLC: application in pharmaceutical products Validação de uma nova metodologia analítica para determinação de bromidrato de fenoterol por CLAE: aplicações em produtos farmacêuticos RIALA6/1475 *Helena Miyoco YANO1, Fernanda Fernandes FARIAS1, Marcelo Beiriz DEL BIANCO1, Pedro Lopez GARCIA2 *Endereço para correspondência: 1Núcleo de Ensaios Físicos e Químicos em Medicamentos, Centro de Medicamentos, Cosméticos e Saneantes, Instituto Adolfo Lutz, Av. Doutor Arnaldo, 355, CEP: 01246-902, São Paulo, SP, Brasil. E-mail: [email protected] 2Departamento de Farmácia, Faculdade de Ciências Farmacêuticas, Universidade de São Paulo, São Paulo, SP, Brasil. Recebido: 31.10.2011- Aceito para publicação: 20.04.2012 RESUMO Bromidrato de fenoterol é um agente agonista adrenérgico β2-seletivo utilizado para tratamento de asma e doenças pulmonares crônicas obstrutivas. A metodologia analítica por cromatografia líquida de alta eficiência (CLAE) foi desenvolvida e validada para a determinação quantitativa de bromidrato de fenoterol. A condição analítica empregada incluiu coluna em fase reversa C18 (150 mm × 3,9 mm d.i., 5 µm) Thermo®, fase móvel composta de mistura de acetonitrila e água (30:70, v/v) com 0,1% de trietilamina e pH ajustado para 5,0 com ácido fórmico, vazão de 1,0 mL.min-1 e detecção em UV a 276 nm. A faixa de linearidade foi de 0,025 a 0,15 mg.mL-1; a curva analítica mostrou coeficiente de correlação > 0,999. O limite de detecção (LD) foi de 0,003 mg.mL-1 e o limite de quantificação de 0,012 mg.mL-1.
    [Show full text]
  • Supplementary Information
    Supplementary Information Network-based Drug Repurposing for Novel Coronavirus 2019-nCoV Yadi Zhou1,#, Yuan Hou1,#, Jiayu Shen1, Yin Huang1, William Martin1, Feixiong Cheng1-3,* 1Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA 2Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH 44195, USA 3Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA #Equal contribution *Correspondence to: Feixiong Cheng, PhD Lerner Research Institute Cleveland Clinic Tel: +1-216-444-7654; Fax: +1-216-636-0009 Email: [email protected] Supplementary Table S1. Genome information of 15 coronaviruses used for phylogenetic analyses. Supplementary Table S2. Protein sequence identities across 5 protein regions in 15 coronaviruses. Supplementary Table S3. HCoV-associated host proteins with references. Supplementary Table S4. Repurposable drugs predicted by network-based approaches. Supplementary Table S5. Network proximity results for 2,938 drugs against pan-human coronavirus (CoV) and individual CoVs. Supplementary Table S6. Network-predicted drug combinations for all the drug pairs from the top 16 high-confidence repurposable drugs. 1 Supplementary Table S1. Genome information of 15 coronaviruses used for phylogenetic analyses. GenBank ID Coronavirus Identity % Host Location discovered MN908947 2019-nCoV[Wuhan-Hu-1] 100 Human China MN938384 2019-nCoV[HKU-SZ-002a] 99.99 Human China MN975262
    [Show full text]
  • Summary of Product Characteristics
    Health Products Regulatory Authority Summary of Product Characteristics 1 NAME OF THE MEDICINAL PRODUCT Salbutamol CFC-Free Inhaler 100 micrograms per metered dose, pressurised inhalation, suspension 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One metered dose contains 100 micrograms of salbutamol (equivalent to 120 micrograms of salbutamol sulphate). This is equivalent to a delivered dose of 90 micrograms of salbutamol (equivalent to 108 micrograms of salbutamol sulphate). For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Pressurised inhalation suspension Pressurised inhalation suspension supplied in an aluminium canister with a metering valve and a plastic actuator and dust cap. 4 CLINICAL PARTICULARS 4.1 Therapeutic Indications Salbutamol CFC-Free Inhaler is indicated in adults, adolescents and children. For babies and children under 4 years of age, see sections 4.2 and 5.1. Salbutamol CFC-Free Inhaler is indicated for the relief and prevention of bronchial asthma and conditions associated with reversible airways obstruction. Salbutamol CFC-Free Inhaler can be used as relief medication in the management of mild, moderate or severe asthma, provided that its use does not delay the introduction and use of regular inhaled corticosteroid therapy, where necessary. 4.2 Posology and method of administration Salbutamol CFC-Free Inhaler is for oral inhalation use only. Posology Adults (including the elderly) and adolescents (children 12 years and over): For the relief of acute bronchospasm, one inhalation (100 micrograms) increasing to two inhalations (200 micrograms), if necessary. To prevent allergen- or exercise-induced symptoms, two inhalations (200 micrograms) should be taken 10-15 minutes before challenge. Maximum daily dose: two inhalations (200 micrograms) up to four times a day.
    [Show full text]
  • Health Reports for Mutual Recognition of Medical Prescriptions: State of Play
    The information and views set out in this report are those of the author(s) and do not necessarily reflect the official opinion of the European Union. Neither the European Union institutions and bodies nor any person acting on their behalf may be held responsible for the use which may be made of the information contained therein. Executive Agency for Health and Consumers Health Reports for Mutual Recognition of Medical Prescriptions: State of Play 24 January 2012 Final Report Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Acknowledgements Matrix Insight Ltd would like to thank everyone who has contributed to this research. We are especially grateful to the following institutions for their support throughout the study: the Pharmaceutical Group of the European Union (PGEU) including their national member associations in Denmark, France, Germany, Greece, the Netherlands, Poland and the United Kingdom; the European Medical Association (EMANET); the Observatoire Social Européen (OSE); and The Netherlands Institute for Health Service Research (NIVEL). For questions about the report, please contact Dr Gabriele Birnberg ([email protected] ). Matrix Insight | 24 January 2012 2 Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Executive Summary This study has been carried out in the context of Directive 2011/24/EU of the European Parliament and of the Council of 9 March 2011 on the application of patients’ rights in cross- border healthcare (CBHC). The CBHC Directive stipulates that the European Commission shall adopt measures to facilitate the recognition of prescriptions issued in another Member State (Article 11). At the time of submission of this report, the European Commission was preparing an impact assessment with regards to these measures, designed to help implement Article 11.
    [Show full text]
  • Ep 2560611 B1
    (19) TZZ Z___T (11) EP 2 560 611 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 9/00 (2006.01) 03.01.2018 Bulletin 2018/01 (86) International application number: (21) Application number: 11719211.2 PCT/EP2011/056227 (22) Date of filing: 19.04.2011 (87) International publication number: WO 2011/131663 (27.10.2011 Gazette 2011/43) (54) "PROCESS FOR PROVIDING PARTICLES WITH REDUCED ELECTROSTATIC CHARGES" VERFAHREN ZUR BEREITSTELLUNG VON PARTIKELN MIT REDUZIERTEN ELEKTROSTATISCHEN LADUNGEN PROCÉDÉ DE PRÉPARATION DE PARTICULES AYANT DES CHARGES ÉLECTROSTATIQUES RÉDUITES (84) Designated Contracting States: • GUCHARDI ET AL: "Influence of fine lactose and AL AT BE BG CH CY CZ DE DK EE ES FI FR GB magnesium stearate on low dose dry powder GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO inhaler formulations", INTERNATIONAL PL PT RO RS SE SI SK SM TR JOURNAL OF PHARMACEUTICS, ELSEVIER BV, NL LNKD- DOI:10.1016/J.IJPHARM.2007.06.041, (30) Priority: 21.04.2010 EP 10160565 vol. 348, no. 1-2, 19 December 2007 (2007-12-19), pages 10-17, XP022393884, ISSN: 0378-5173 (43) Date of publication of application: • ELAJNAF A ET AL: "Electrostatic 27.02.2013 Bulletin 2013/09 characterisation of inhaled powders: Effect of contact surface and relative humidity", (73) Proprietor: Chiesi Farmaceutici S.p.A. EUROPEAN JOURNAL OF PHARMACEUTICAL 43100 Parma (IT) SCIENCES, ELSEVIER, AMSTERDAM, NL LNKD- DOI:10.1016/J.EJPS.2006.07.006, vol. 29, no. 5, 1 (72) Inventors: December 2006 (2006-12-01), pages 375-384, • COCCONI, Daniela XP025137181, ISSN: 0928-0987 [retrieved on I-43100 Parma (IT) 2006-12-01] • MUSA, Rossella • CHAN ET AL: "Dry powder aerosol drug I-43100 Parma (IT) delivery-Opportunities for colloid and surface scientists", COLLOIDS AND SURFACES.
    [Show full text]
  • 2019 Year in Review: Aerosol Therapy
    2019 Year in Review: Aerosol Therapy Ariel Berlinski Introduction COPD Newly Approved Drugs Asthma New Devices As-Needed Inhaled Corticosteroid/Long-Acting Bronchodilator Therapy Asthma Medication Report in Adolescents and Caregivers Cystic Fibrosis Hypertonic Saline in Cystic Fibrosis Infectivity of Cough Aerosols in Cystic Fibrosis Liposomal Amikacin for MAC Lung Disease Electronic Nicotine Delivery Systems E-Cigarette or Vaping Associated Lung Injury Secondhand Exposure Summary Relevant publications related to medicinal and toxic aerosols are discussed in this review. Treatment of COPD includes a combination of long-acting bronchodilators and long-acting muscarinic antagonists. A combination of aclidinium bromide and formoterol fumarate was approved in the United States. The combination was superior to its components alone, as well as tiotropium and a salmeterol-fluticasone combination. Increased risk of an asthma exacerba- tion was reported in children exposed to electronic nicotine delivery systems. A smart inhaler capable of recording inspiratory flow was approved in the United States. The use of as-needed budesonide-formoterol was reported to be superior to scheduled budesonide and as-needed ter- butaline for the treatment of adults with mild-to-moderate asthma. A survey among teens with asthma and their caregivers revealed a disagreement in the number of inhaled controller medi- cations the teen was taking. Treatment with inhaled hypertonic saline resulted in a decreased lung clearance index in infants and preschool children with cystic fibrosis. Surgical masks were well tolerated and significantly decreased the burden of aerosolized bacteria generated by coughing in adults with cystic fibrosis. Inhaled liposomal amikacin in addition to guideline- based therapy was reported to be superior to guideline-based therapy alone in achieving nega- tive sputum cultures in adult subjects with Mycobacterium avium complex pulmonary disease.
    [Show full text]
  • Terbutaline Sulfate Injection, USP
    Terbutaline Sulfate Injection, USP 1 mg per mL | NDC 70860-801-01 ATHENEX AccuraSEESM PACKAGING AND LABELING BIG, BOLD AND BRIGHT — TO HELP YOU SEE IT, SAY IT AND PICK IT RIGHT DIFFERENTIATION IN EVERY LABEL, DESIGNED TO HELP REDUCE MEDICATION ERRORS PLEASE SEE FULL PRESCRIBING INFORMATION, INCLUDING BOXED WARNING, FOR TERBUTALINE SULFATE INJECTION, USP, ENCLOSED. THE NEXT GENERATION OF PHARMACY INNOVATION To order, call 1-855-273-0154 or visit www.Athenexpharma.com Terbutaline Sulfate Injection, USP 1 mg NDC 70860-801-01 1 mg per mL DESCRIPTION Glass Vial CONCENTRATION 1 mg per mL CLOSURE 13 mm UNIT OF SALE 10 vials BAR CODED Yes CHOOSE AccuraSEESM FOR YOUR PHARMACY Our proprietary, differentiated and highly-visible label designs can assist pharmacists in accurate medication selection. With a unique AccuraSEE label design for every Athenex product, we’re helping your pharmacy to reduce the risk of medication errors. The idea is simple: “So what you see is exactly what you get.” Athenex, AccuraSEE and all label designs are copyright of Athenex. ©2019 Athenex. APD-0022-02-4/19 To order, call 1-855-273-0154 or visit www.Athenexpharma.com TERBUTALINE SULFATE Injection, USP • The use of beta-adrenergic agonist bronchodilators • Terbutaline sulfate should be used during nursing alone may not be adequate to control asthma in only if the potential benefit justifies the possible risk INDICATIONS AND USAGE many patients. Early consideration should be given to to the newborn. • Terbutaline sulfate injection is indicated for the adding anti-inflammatory agents, e.g., corticosteroids. prevention and reversal of bronchospasm in patients ADVERSE REACTIONS 12 years of age and older with asthma and reversible • Terbutaline sulfate should be used with caution • Common adverse reactions reported with terbutaline bronchospasm associated with bronchitis and emphysema.
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • Β2 Adrenergic Agonist Suppresses Eosinophil-Induced Epithelial-To- Mesenchymal Transition of Bronchial Epithelial Cells Keigo Kainuma1,2, Tetsu Kobayashi3, Corina N
    Kainuma et al. Respiratory Research (2017) 18:79 DOI 10.1186/s12931-017-0563-4 RESEARCH Open Access β2 adrenergic agonist suppresses eosinophil-induced epithelial-to- mesenchymal transition of bronchial epithelial cells Keigo Kainuma1,2, Tetsu Kobayashi3, Corina N. D’Alessandro-Gabazza2, Masaaki Toda2, Taro Yasuma2, Kota Nishihama2, Hajime Fujimoto3, Yu Kuwabara1,2, Koa Hosoki1,2, Mizuho Nagao1, Takao Fujisawa1 and Esteban C. Gabazza2* Abstract Background: Epithelial-mesenchymal transition is currently recognized as an important mechanism for the increased number of myofibroblasts in cancer and fibrotic diseases. We have already reported that epithelial- mesenchymal transition is involved in airway remodeling induced by eosinophils. Procaterol is a selective and full β2 adrenergic agonist that is used as a rescue of asthmatic attack inhaler form and orally as a controller. In this study, we evaluated whether procaterol can suppress epithelial-mesenchymal transition of airway epithelial cells induced by eosinophils. Methods: Epithelial-mesenchymal transition was assessed using a co-culture system of human bronchial epithelial cells and primary human eosinophils or an eosinophilic leukemia cell line. Results: Procaterol significantly inhibited co-culture associated morphological changes of bronchial epithelial cells, decreased the expression of vimentin, and increased the expression of E-cadherin compared to control. Butoxamine, a specific β2-adrenergic antagonist, significantly blocked changes induced by procaterol. In addition, procaterol inhibited the expression of adhesion molecules induced during the interaction between eosinophils and bronchial epithelial cells, suggesting the involvement of adhesion molecules in the process of epithelial-mesenchymal transition. Forskolin, a cyclic adenosine monophosphate-promoting agent, exhibits similar inhibitory activity of procaterol. Conclusions: Overall, these observations support the beneficial effect of procaterol on airway remodeling frequently associated with chronic obstructive pulmonary diseases.
    [Show full text]
  • Ep 2626065 A1
    (19) TZZ Z_T (11) EP 2 626 065 A1 (12) EUROPEAN PATENT APPLICATION published in accordance with Art. 153(4) EPC (43) Date of publication: (51) Int Cl.: A61K 31/137 (2006.01) A61K 31/135 (2006.01) 14.08.2013 Bulletin 2013/33 A61K 31/4704 (2006.01) A61K 31/58 (2006.01) A61K 31/56 (2006.01) A61K 9/12 (2006.01) (2006.01) (2006.01) (21) Application number: 11827927.2 A61K 9/14 A61P 11/06 (86) International application number: Date of filing: 01.02.2011 (22) PCT/CN2011/070883 (87) International publication number: WO 2012/041031 (05.04.2012 Gazette 2012/14) (84) Designated Contracting States: (72) Inventor: WU, Wei-hsiu AL AT BE BG CH CY CZ DE DK EE ES FI FR GB Taipei GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO Taiwan (TW) PL PT RO RS SE SI SK SM TR (74) Representative: Patentanwaltskanzlei WILHELM (30) Priority: 28.09.2010 CN 201010502339 & BECK Prinzenstrasse 13 (71) Applicant: Intech Biopharm Ltd. 80639 München (DE) Taipei (TW) (54) COMPOUND COMPOSITION FOR INHALATION USED FOR TREATING ASTHMA (57) An inhaled pharmaceutical composition con- tric way as a controller. The eccentric way control therapy tains primary active ingredients of beta2- agonist and cor- could create a low blood concentration period during the ticosteroids.The pharmaceuticalcompositions disclosed day and minimize the acute tolerance phenomenon (or in the present invention are to be inhaled by a patient so called tachyphylaxis) for bronchodilator - beta2-ago- when needed as a reliever, or administrated in an eccen- nists in treating asthma or other obstructive respiratory disorders.
    [Show full text]